37 results about "Donors organ" patented technology

Systems and methods are provided herein for monitoring electrical activity in ex vivo, resting donor organs. Systems and methods provided herein also include providing electrical stimulation to the donor tissue to maintain or increase viability during storage or transport. Donor organs can include ex vivo, resting hearts. Electrical activity can be used to determine donor organ viability, especially in instances where visual evaluation of a beating heart is not possible. The same electrodes or other sensing devices used to measure electrical activity can be used to apply a voltage / current to the tissue as well in order to maintain viability of the organ. In some embodiments, stimulation or depression may be provided in response to the measured electrical activity.

Systems and methods of the invention generally relate to prolonging viability of bodily tissue, especially lung tissue, through the use of an expandable accumulator to maintain a constant pressure within the lumen of the organ even during external pressure fluctuations due to, for example, flight. Systems and methods may include prolonging donor organ viability in storage through the use of an organ container that mimics the geometry and orientation of the organ in vivo.

Systems and methods of the invention generally relate to prolonging viability of bodily tissue, especially lung tissue, through the use of an expandable accumulator to maintain a constant pressure within the lumen of the organ even during external pressure fluctuations due to, for example, flight. Systems and methods may include prolonging donor organ viability in storage through the use of an organ container that mimics the geometry and orientation of the organ in vivo.

Systems and methods of the invention generally relate to prolonging viability of bodily tissue, especially lung tissue, through the use of an expandable accumulator to maintain a constant pressure within the lumen of the organ even during external pressure fluctuations due to, for example, flight. Systems and methods may include prolonging donor organ viability in storage through the use of an organ container that mimics the geometry and orientation of the organ in vivo.

A method of storing a donor organ prior to implantation into an organ recipient includes bagging the donor organ by placing the donor organ into at least one bag and sealing the at least one bag; placing the bagged donor organ into a portable storage container; placing at least one cooling pack in the portable storage container, wherein the at least one cooling pack is configured to maintain a temperature of the donor organ at 8 to 12 degrees C. during storage of the donor organ, and storing the donor organ in the portable storage container prior to transplanting the donor organ into the organ recipient, wherein the portable storage container does not contain any ice at any time during storage of the donor organ.

Systems and methods of the invention generally relate to prolonging viability of bodily tissue, especially lung tissue, through the use of an expandable accumulator to maintain a constant pressure within the lumen of the organ even during external pressure fluctuations due to, for example, flight. Systems and methods may include prolonging donor organ viability in storage through the use of an organ container that mimics the geometry and orientation of the organ in vivo.

Systems and methods of the invention generally relate to prolonging viability of bodily tissue, especially lung tissue, through the use of an expandable accumulator to maintain a constant pressure within the lumen of the organ even during external pressure fluctuations due to, for example, flight. Systems and methods may include prolonging donor organ viability in storage through the use of an organ container that mimics the geometry and orientation of the organ in vivo.

A system and method for rendering a diseased organ implant eligible, the method including acquiring an image data set of a potential donor organ, identifying one or more disease states in the potential donor organ, wherein the one or more disease states render the organ ineligible for transplant, harvesting the potential donor organ, applying histotripsy therapy, and confirming elimination / reduction of the disease state in the potential donor organ.

The disclosure provides, in various embodiments, systems, devices and methods relating to ex-vivo organ care. In certain embodiments, the disclosure relates to maintaining an organ ex-vivo at near-physiologic conditions. The present application describes, for example, a method for using lactate measurement in the arterial and the venous blood lines of the Organ Care System Heart perfusion device to evaluate, for example, the: 1) overall perfusion status of an isolated heart; 2) metabolic status of an isolated heart; and 3) overall vascular patency of an isolated donor heart. This aspect of the present disclosure may use, for example, the property of myocardial cell's unique ability to produce / generate lactate when they are starved for oxygen and metabolize / utilize lactate for energy production when they are well perfused with oxygen.

This present disclosure relates to the use of donor organ-derived microvesicles to monitor the status of a transplanted organ in a subject. Accordingly, this disclosure provides for methods and kits for isolating, purifying and / or identifying donor organ-derived microvesicles from a biological sample of a subject. In certain embodiments, a method for isolating, purifying and / or identifying donor organ-derived microvesicles includes obtaining a biological sample from the subject and isolating, purifying or identifying a donor organ-derived microvesicle from the biological sample by the detection of a protein specific for the donor.

A method of preserving a donor organ for transplantation may include flushing the donor organ with flush solution comprising itaconate and storing the flushed donor organ. The flush solution may comprise dimethyl itaconate (DI) in an amount greater than or equal to 0.1 mM and less than or equal to 0.75 mM. Following removal from storage, the donor organ may be perfused using an ex vivo organ perfusion (EVOP) process. The perfusate may also include itaconate.

A perfusion stock composition, for preserving a donor organ for transplantation, comprising: a source of 60 to 100 mM Na+; a source of 10 to 20 mM K+; a source of 5 to 10 mM Mg2+; a source of 0.25 to 0.75 mM Ca2+; 10 to 40 mM Tris(hydroxymethyl)aminomethane hydrochloride (Tris or THAM), 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 3-(N-morpholino)propanesulfonic acid (MOPS), 2-(N-morpholino)ethanesulfonic acid (IviES), N,N-bis-(2-hydroxyethyl)-2-aminoethanesulfonic acid (BES), or N / -tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid (TES); a source of 10 to 30 mM HCO3; 1 to 30 mM glucose; 1 to 20 U / L insulin; 1 to 10 mM fructose diphosphate or a salt thereof, 1 to 40 mM aspartate or glutamate; 1 to 10 mM adenosine, cAMP or cGMP; 1 to 10 mM reduced glutathione; and 30 to 100 mM lactobionate or mannitol; and, optionally, a diluent. The present disclosure also provides a perfusion composition, a kit, a method, and a perfusion apparatus, each related to the perfusion stock composition.

Systems and methods of the invention generally relate to prolonging viability of bodily tissue, especially lung tissue, through the use of an expandable accumulator to maintain a constant pressure within the lumen of the organ even during external pressure fluctuations due to, for example, flight. Systems and methods may include prolonging donor organ viability in storage through the use of an organ container that mimics the geometry and orientation of the organ in vivo.

Materials and methods for restoring an ex vivo organ prior to transplantation of the organ into a subject in need thereof are provided. The methods and materials are useful for treating, improving, restoring, and / or regenerating organs, such as kidney and liver, the organ is aged and / or characterized by organ injury caused by ischemic injury, toxic injury, perfusion injury, hypertension injury, immune injury, physical injury, steatosis, virus-induced hepatitis, alcohol or fibrosis irrelevant to any known cause. Materials and methods provided may increase the available library of donor organs, such as kidneys and livers. In addition, the provided materials and methods can treat organs that are then autotransplanted.

The utility model discloses a donor organ storing, transferring and carrying device in organ transplantation. The donor organ storing, transferring and carrying device comprises a transferring box; the transfer box comprises a transfer box body and a box cover. The box cover is fixedly connected with the transfer box main body through a hinge; the transfer box body is a hollow cavity, and an organ storage mechanism is arranged in the middle of the cavity. The organ storage mechanism comprises a fixing seat and an organ placing basket from outside to inside, and through grooves are formed in the peripheries of the organ placing basket and the fixing seat in a circumferential array mode; the fixed seat is fixedly arranged in the middle of the cavity; the organ placement basket is hollowly placed in the fixed seat; a detachable organ placing basket cover and a fixing seat cover are respectively arranged at the upper ends of the organ placing basket and the fixing seat; the device can monitor the temperature in the box, and meanwhile, the timing device is arranged to record the storage time of organs in the box; corresponding devices are arranged in the box and can separate ice blocks from organs, and the organs are prevented from being frostbitten.

A perfusion stock composition, for preserving a donor organ for transplantation, comprising: a source of 60 to 100 mM Na+; a source of 10 to 20 mM K+; a source of 5 to 10 mM Mg2+; a source of 0.25 to 0.75 mM Ca2+; 10 to 40 mM Tris(hydroxymethyl)aminomethane hydrochloride (Tris or THAM), 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 3-(N-morpholino)propanesulfonic acid (MOPS), 2-(N-morpholino)ethanesulfonic acid (IviES), N,N-bis-(2-hydroxyethyl)-2-aminoethanesulfonic acid (BES), or N / -tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid (TES); a source of 10 to 30 mM HCO3; 1 to 30 mM glucose; 1 to 20 U / L insulin; 1 to 10 mM fructose diphosphate or a salt thereof; 1 to 40 mM aspartate or glutamate; 1 to 10 mM adenosine, cAMP or cGMP; 1 to 10 mM reduced glutathione; and 30 to 100 mM lactobionate or mannitol; and, optionally, a diluent. The present disclosure also provides a perfusion composition, a kit, a method, and a perfusion apparatus, each related to the perfusion stock composition.

Methods and materials for improving outcomes for ex vivo perfused organs are provided herein. For example, this document provides methods and materials that can be used to assess and treat lungs during ex vivo perfusion prior to transplantation.

Provided are materials and methods for rejuvenating an ex vivo organ prior to transplantation of the organ into a subject in need thereof. The methods and materials can be used, for example, to treat, ameliorate, rejuvenate, and / or regenerate organs, e.g., kidneys and livers, that are of old age and / or characterized by organ damage due to an ischemic injury, a toxic injury, a perfusion injury, a hypertensive injury, an immune injury, a physical injury, steatosis, virus induced hepatitis, alcohol, or fibrosis not associated with any known cause. The materials and methods provided can increase the pool of available donor organs, e.g., kidneys and livers. Furthermore, the materials and methods provided can treat an organ that is then self-transplanted.

The invention discloses a kidney transplantation donor organ activity real-time monitoring system and method in the technical field of isolated organ perfusion, and the system comprises a multi-modal sensing module which is used for sensing multi-modal data of molecular action generation, cell mechanical characteristics and organ functions of an isolated kidney in a cross-scale manner; the perfusion dynamic regulation and control module is used for fusing multi-modal data based on a learning algorithm and optimizing perfusion parameters in real time; and the bionic normal-temperature perfusion module is used for simulating a human physiological environment and maintaining kidney activity by using a micro-fluidic chip technology and a self-adaptive oxygenation technology based on the optimized perfusion parameters. A cross-scale multi-modal monitoring system is constructed, multi-modal data of the in-vitro kidney is sensed, dynamic perfusion regulation and control based on a learning algorithm are developed by fusing the multi-modal data, self-adaptive optimization of perfusion parameters is achieved, a perfusion environment similar to human physiology is created for the in-vitro kidney, and therefore the DGF risk is effectively reduced, and the in-vitro kidney perfusion system is suitable for in-vitro kidney perfusion. The success rate of kidney transplantation and the long-term survival rate of donor organs are improved.

Systems and methods of the invention generally relate to prolonging viability of bodily tissue, especially lung tissue, through the use of an expandable accumulator to maintain a constant pressure within the lumen of the organ even during external pressure fluctuations due to, for example, flight. Systems and methods may include prolonging donor organ viability in storage through the use of an organ container that mimics the geometry and orientation of the organ in vivo.

The present invention relates to the technical field of surgical instruments used in donor organ transplantation. Disclosed is an integrated puncture and perfusion catheter for perfusion of donor abdominal organs for transplantation, comprising: a puncture cylinder, wherein a reservoir is fixedly connected to a puncture end of the puncture cylinder; and further comprising: a puncture and perfusion switching mechanism, wherein the puncture and perfusion switching mechanism is arranged at the center of the puncture cylinder, and is used for freely switching the puncture and perfusion functions of the puncture cylinder at the same position. Through cooperation of provided structures such as a first rack, a second rack, and a guide member, the rotation of a gear disc can be used to control the first rack and the second rack to slide in opposite directions of the puncture cylinder, such that a puncture tip moves backward upon the completion of penetration to provide clearance, thereby avoiding damage to tunica intima caused by retention of the puncture tip, and improving the viability of a harvested organ; and the second rack carries a support tube by means of the guide member to move towards the perfusion position, and the support tube replaces the puncture tip at the puncture position, such that a perfusion pipe is prevented from deviating from a puncture port, thereby minimizing perfusate usage costs.

An donor organ viability instrument (1000) includes an in situ donor organ interrogation module with a positioned photoacoustic array (1008). This array, tailored for the organ type and viability factors, performs computational photoacoustic imaging to generate viability data for the donor organ (1028) in its natural location. In some implementations, the instrument includes an ex vivo donor organ interrogation module (4000) with a stationary photoacoustic array (1007). This array, also tailored for the organ type and viability factors, performs computational photoacoustic imaging and multispectral scanning on an organ placed in an acoustic coupling nest (4016). Additionally, it includes sensors for gravimetric, dimensional, and environmental measurements to assess organ viability. In certain implementations, the apparatus includes a predictive model with machine learning algorithms trained on a plurality of feature signals (6002) and corresponding organ responses (6004).

This present disclosure relates to the use of donor organ-derived microvesicles to monitor the status of a transplanted organ in a subject. Accordingly, this disclosure provides for methods and kits for isolating, purifying and / or identifying donor organ-derived microvesicles from a biological sample of a subject. In certain embodiments, a method for isolating, purifying and / or identifying donor organ-derived microvesicles includes obtaining a biological sample from the subject and isolating, purifying or identifying a donor organ-derived microvesicle from the biological sample by the detection of a protein specific for the donor.

A method of storing a donor organ prior to implantation into an organ recipient includes bagging the donor organ by placing the donor organ into at least one bag and sealing the at least one bag; placing the bagged donor organ into a portable storage container; placing at least one cooling pack in the portable storage container, wherein the at least one cooling pack is configured to maintain a temperature of the donor organ at 8 to 12 degrees C. during storage of the donor organ, and storing the donor organ in the portable storage container prior to transplanting the donor organ into the organ recipient, wherein the portable storage container does not contain any ice at any time during storage of the donor organ.

A medical device for thermally treating a donor organ to be transplanted within a patient, comprises a jacket. The jacket includes a first section and a second section adjacent to the first section. The first and second sections are folded about a hinge to form a pocket sized to receive the donor organ. The first and second sections are secured together by a plurality of conjoined weld bar sets. A sling depends from the second section and has a strap. The strap includes a first end portion coupled to the sling, and an opposite second end portion affixed to one set of the plurality of conjoined weld bar sets.

Systems and methods of the invention generally relate to prolonging viability of bodily tissue, especially lung tissue, through the use of an expandable accumulator to maintain a constant pressure within the lumen of the organ even during external pressure fluctuations due to, for example, flight. Systems and methods may include prolonging donor organ viability in storage through the use of an organ container that mimics the geometry and orientation of the organ in vivo.

The utility model relates to the technical field of donor organ trimming, and discloses an operating table chair for donor organ trimming, which comprises an operating table and an operating chair, the operating table comprises a table top, the corners of the bottom end of the table top are respectively provided with a stand column, and the bottom of each stand column is provided with a universal wheel; a through groove is formed in one side of the middle of the table top, the through groove and the operation basin are buckled and fixed, the operation basin is used for containing a donor organ to be trimmed, wedging grooves are formed in the edge portions, on the two sides of the through groove, of the table top, and the wedging grooves are sunken inwards to be in an arc shape. The operation basin is arranged in the through groove of the table top, the fit grooves with the semicircular radians designed in a humanized mode on the two sides are attached to the face of the human body, it is guaranteed that the body position of medical staff is comfortable after long-time operation in the operation, the adaptive chair facilitates height adjustment of the medical staff so that the medical staff can be adjusted to the most suitable operation height for operation, and the comfort level of the medical staff is improved; therefore, precise processing of fine parts such as organ blood vessels can be ensured.

The present invention relates to methods of treating or preventing ischemia reperfusion injury (IRI) in a subject receiving a donor organ transplant, wherein the methods involve administration of a complement factor 2 (C2) inhibitor to the subject. The present invention also relates to methods of improving allograft function and also to methods of reducing the risk of allograft loss in a subject receiving a donor organ transplant, wherein the methods involve administration of a C2 inhibitor to the subject. Furthermore, the present invention relates to methods of treating or preventing delayed graft function (DGF) in a subject receiving a kidney transplant, wherein the methods involve administration of a C2 inhibitor to the subject. The C2 inhibitor may be empasiprubart.

Provided are materials and methods for rejuvenating an ex vivo organ prior to transplantation of the organ into a subject in need thereof. The methods and materials can be used, for example, to treat, ameliorate, rejuvenate, and / or regenerate organs, e.g., kidneys and livers, that are of old age and / or characterized by organ damage due to an ischemic injury, a toxic injury, a perfusion injury, a hypertensive injury, an immune injury, a physical injury, steatosis, virus induced hepatitis, alcohol, or fibrosis not associated with any known cause. The materials and methods provided can increase the pool of available donor organs, e.g., kidneys and livers. Furthermore, the materials and methods provided can treat an organ that is then self-transplanted.

The invention disclosed herein provides methods and materials designed to improve organ transplantation outcomes. Embodiments of the invention include methods for administering the drug belumosudil to patients who have undergone an organ or other tissue transplantation (e.g., transplantation of a solid donor organ such as a kidney and / or receiving an infusion of donor stem cells such as CD34+ cells). In these methods, transplantation patients to whom belumosudil is administered are selected to be those not suffering from graft versus host disease (GVHD).